26th Annual Biotech in Europe Forum

26th Annual Biotech in Europe Forum

FOR GLOBAL PARTNERING & INVESTMENT

7th - 8th of October 2026|MÖVENPICK HOTEL | BASEL | SWITZERLAND

We are pleased to announce that the 26th Annual Biotech in Europe Forum (#Sachs_BEF) will take place on the 7th – 8th of October 2026 at the Mövenpick Hotel Basel. The event will be part of the Sachs Autumn Life Sciences Week (#SALSW), which will also incorporate the 1st Annual European Healthcare Impact Summit (#Sachs_EHIS), taking place the day before BEF. The new forum will replace the 13th Annual HealthTech Investment Forum (#Sachs_HTIF) and the 8th Annual HealthTech Innovation Days, allowing relevant attendees to register for all three days of SALSW.

The physical programme for BEF will consist of the usual panels and keynotes, which will be available on-demand by the 15th of October. Additionally, there will be pre-arranged in-person meetings, live and on-demand company showcases, as well as networking receptions. This year, the main reception on the 7th of October will take place at Grand Hotel Les Trois Rois, one of Basel’s most prestigious riverside venues, offering an elegant setting for high-level networking​. Recordings of the presentations will be uploaded by the 13th of October. During the Online Partnering Week, virtual meetings will be available through the Online Meeting System.

Returning for its 26th Annual Edition, this established global bio-pharma industry event will address the key challenges and investment trends for 2026, with a strong focus on partnering, alliance management, and future prospects. Leading industry figures will contribute their insights through a series of panel discussions covering the broader market outlook, as well as innovation across different therapeutic sectors.

The main programme for the 26th Annual BEF is spread throughout 2 days (7th - 8th of October) and will feature more than 15 hours of high-level keynotes and panel discussions. In addition, there will be a global company showcase of 50+ presentations by established public, private, emerging, and seed companies, offering innovative solutions and seeking investment and partnering opportunities. This will include a limited number of live presentations taking place in dedicated parallel presentation tracks, including the plenary Rising Stars – Biotech Seed Companies Session, covering biotech, drug discovery, and diagnostic start-ups from across Europe. In addition, there will be virtual company showcases available on demand during the virtual week.

We anticipate 650+ delegates will register for the forum from across the life sciences sector, bringing together a global audience of senior pharma, biotech, and HealthTech executives, bankers, consultants, and financial and corporate investors, alongside a select number of service providers, with part of the audience also participating virtually. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by our regular media partners.

The In-Person meetings will take place during the physical event on the 7th - 8th of October, while virtual meetings will be held on the 13th - 15th of October. For virtual meetings, the system will allow you to have a secure audio/video call, as well as the option to present slides using a screen share function, and we will have a dedicated room for in-person meetings. We expect over 2000 meetings to be completed during SALSW. The conference will be held in the Central European Summer Time (CEST) zone. 

BRONZE SPONSORS:

Lilly and Company
Merck KGaA, Darmstadt, Germany
Oppenheimer & Co. Inc.
​Paris-Saclay Cancer Cluster

CONTRIBUTING SPONSORS:

Baker McKenzie
​Cancer Research Horizons
Ropes & Gray

RECEPTION SPONSOR:

Ropes & Gray

Panels & Sessions on the 7th of October Include:

  • State of the Industry Panel
  • Morning Keynote on Day 1: "The Biotech Briefing: Capital Markets & M&A Playbook"
  • VC & Private Equity Investor Roundtable
  • Second Keynote Speech Day 1
  • Advances in Immunology & Inflammation Panel: Investor Perspectives
  • Investment Opportunities in Women’s Health Panel
  • Neuroscience Innovation Panel

Panels & Sessions on the 8th of October Include:

  • Pharma Strategy & Dealmaking Panel
  • Keynote / Workshop Day 2
  • China Partnering & Investment Panel
  • Latest Trends in Oncology Partnering Panel
  • Advanced Oncology Investment Panel
  • Investing in Early-Stage Innovation Panel
  • Rising Stars – Biotech Seed Companies Session

In-Person Meetings:

  • 7th - 8th of October

Online Virtual Meetings:

  • 13th - 15th of October

Reception:

  • 7th of October at Grand Hotel Les Trois Rois ​– Main Networking Reception
  • 8th of October – ​Farewell Reception

Keynote Speakers:

Jonathan Javitt
CEO, NRx Pharmaceuticals, Inc.
Michael Margolis
Senior Managing Director, Co-Head, Healthcare Investment Banking, Oppenheimer & Co. Inc.

Chairs & Speakers:

Alexander Gebauer
Co-Founder & Executive Chairman, Galimedix Therapeutics, Inc.
Allan Marchington
Managing Director, Head of Life Sciences, Intermediate Capital Group PLC
Anastasiya Sybirna
Principal, Jeito Capital
Anu Balendran
Head BD&L Transactions, CRM, Novartis Pharma AG
Audrey Cacaly
Principal, Forbion
Barbara Castellano
Partner, Panakès Partners SGR SpA
Birgit Steckel-Hamann
Associate VP, External Innovation, Search & Evaluation, Cardiometabolic Health, Eli Lilly and Company
Chandra Leo
Investment Advisor, HBM Partners AG
Corinne Venot
VP, Global Business Development, BeOne Medicines I GmbH
Daniel Marshall
Senior Director, Search & Evaluation, Oncology R&D, BD, AstraZeneca
Daniel Rankin
SVP, Head of Strategy & Corporate Development, Sobi
Darren Ji
Co-Founder, Chairman & CEO, Elpiscience Biopharmaceuticals Co. Ltd.
Eric Halioua
Executive Chairman, Ervimmune
Eric de la Fortelle
Head of Business Development & Strategy, Institute of Molecular & Clinical Ophthalmology Basel (IOB)
Esteban Pombo-Villar
Board Member, TargImmune Therapeutics AG
Esther Melo
Senior Director BD&L, F. Hoffmann-La Roche AG
Evonne Sepsis
Managing Director, ESC Advisors
Florian Gerard-Mercier
Investment Director, Andera Partners
Georgia Frost
Vice President, Dementia Discovery Fund 2 L.P. (SV Health Investors)
Hannah England
Partner, Ropes & Gray LLP
Hanne Callewaert
Co-Founder & CEO, Astrivax Therapeutics N.V.
Hugh Nuthall
Executive Director, Search & Evaluation Neuroscience, Eli Lilly and Company
Ivana Labudovic
Chief Safety Officer and Head Global Pharmacovigilance, Organon
Jan-Philipp Kruse
Senior Director, Lilly Ventures, Eli Lilly and Company
Jeremy Griggs
Executive Director, Search & Evaluation, GSK
Jerome Marzinski
CEO, OxSonics
Jerry Wu
Venture Partner, LongRiver Investments
Joachim Vogt
Director Search & Evaluation International, AbbVie, Inc.
Jonathan Tobin
Partner, Brandon Capital
Julia Braun
Partner, Baker McKenzie
Julia Rossié
Counsel, Baker McKenzie
Katya Smirnyagina
Senior Partner, Oxford Science Enterprises
Khatereh Ahmadi
Venture Partner, XGEN Venture SGR S.p.A.
Konstantin Petropoulos
CEO, Secarna Pharmaceuticals GmbH & Co. KG
Konstantin von Schulthess
CFO, CDR-Life AG
Maria Dahl
Executive Director, BD&L, Novartis Pharma AG
Mark Bodmer
CEO, Nucleome Therapeutics Ltd.
Michael Altorfer
CEO, Swiss Biotech Association
Michael Hübner
Director External Scientific Innovation, Johnson & Johnson Innovation LLC
Michael Rice
Expert Advisor, SVP, Cell & Gene Therapy, Lumanity
Miquel Vila-Perelló
CEO, SpliceBio S.L
Nuno Alves
Business Development Lead, Astellas Pharma Europe Ltd.
Odile Rundquist
Partner, Bioqube Ventures
Peter Gergely
VP, Global Head of TM for Immunology, Novartis AG
Peter Louwagie
SVP Corporate & Business Development, Genmab A/S
Regina Hodits
Managing Director, Angelini Ventures S.p.A.
Renée Aguiar-Lucander
CEO, Hansa Biopharma AB
Richard Munton
Senior Business Development Director, F. Hoffmann-La Roche
Sam Fazeli
Head of Research, Global Industries & Senior Pharmaceuticals Analyst, Bloomberg Intelligence
Samuel Black
Director Business Development Neurology & Immunology, Merck KGaA, Darmstadt, Germany
Sara Zhou
Founding Partner, Intercontinental Capital
Sarah Holland
President of Swiss Healthcare Licensing Group & CBO, CDR-Life AG
Stefan Luzi
Partner, Gilde Healthcare Partners B.V.
Stephan Emmerth
Director, BaseLaunch
Thaminda Ramanayake
CEO, Anaveon AG
Thibaut Roulon
Senior Investment Director, Bpifrance
Tim Haines
Executive Partner, Managing Director, Abingworth LLP
Vanessa Carle
Principal, Forbion
Zhizhong Yao
Partner Sofinnova Biovelocita, Sofinnova Partners SAS

Presenting Companies:

ADOCIA logo
Adularia AG logo
Altrovia
Amporin Pharmaceuticals AG logo
Anaveon AG
CARTemis Therapeutics GmbH
Cereus Biosciences
Curlim logo
Eleva GmbH logo
ExpreS2ion Biotech Holding AB logo
FINNCURE Ltd. logo
Galimedix Therapeutics, Inc. logo
kez.biosolutions GmbH logo
Ksilink logo
Maeve Therapeutics
Micreos Pharma logo
Nerai Bioscience AG logo
Noetica Pharma
Nucleome Therapeutics Ltd.
Nucleus Network Ltd logo
Oncostellae
OxSonics logo
PharmNovo AB
SpliceBio, S.L logo
TAXIS Pharmaceuticals, Inc. logo

Previous Highlights:

26th Annual Biotech in Europe Forum event highlight
26th Annual Biotech in Europe Forum event highlight
26th Annual Biotech in Europe Forum event highlight
26th Annual Biotech in Europe Forum event highlight
26th Annual Biotech in Europe Forum event highlight

To learn more about presenting, exhibiting or sponsorship opportunities, please contact us at SachsTeam@SachsForum.com or call us on + 44 203 463 4890.